OncoHost develops personalized strategies to maximize the success of cancer therapy. Utilizing proprietary proteomic analysis, we aim to understand the patient's unique response to therapy and overcome one of the major obstacles in clinical oncology today – resistance to therapy. Based on robust scientific infrastructure and a strong IP position, OncoHost is launching an extensive clinical program with leading academic and clinical partners.
OncoHost's platform analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to given cancer therapy. Response Profiling also identifies potential drug targets, advancing the development of novel therapeutic strategies.OncoHost's profiling platform offers a new layer of information, enabling early identification of non-responsiveness to cancer treatments and the discovery of new targets to overcome treatment resistance.
B2B
1 to 25
Series B
$16 M
Scaling Up
2017
Pharmaceuticals
Healthcare
Health Care Facilities & Hospitals
Biotechnology
Improves Clinical Trial Success Rate
Improved Outcomes & Reduced Side Effects
Increase Efficiency
N/A
Yes
Active
Machine Learning
Natural Language Processing
Automated Planning and Search
Software
N/A
Dec 2021
- OncoHost Collaborates with Lung Biobank Heidelberg
4
1
$35M
Company was founded 2017 and it took almost 5 years (May 2022) to raise first external round
Investors
Interested in researching OncoHost?
We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about OncoHost
Potential Customers
Interested in what they do or partnership?
Learn more about how they work